iDose TR Administration in an Office-Based Surgery Setting

NCT07816692 · tracked via the Priya Life Science USA tracker

Sponsor

Glaukos Corporation

Phase

—

Started

2026-05-13

Last updated

2026-09-14

Condition(s) studied

Open Angle Glaucoma (OAG)Ocular Hypertension (OHT)

Investigational drug(s) / intervention(s)

iDose TR (travoprost intracameral implant) 75 µg

iDose TR (travoprost intracameral implant) 75 µg: Travoprost-releasing implant preloaded in a sterile, single-use inserter.

Study summary

Clinical in-use observational trial to evaluate the administration of iDose TR (travoprost intracameral implant) in an office-based surgery setting.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Diagnosis of Open angle glaucoma (OAG) or ocular hypertension (OHT) Exclusion Criteria: * Prior administration of iDose TR or administration of an investigational intracameral implant in the study eye Active ocular infection or inflammation History of hypersensitivity to travoprost or implant components Recent ocular surgery Uncontrolled systemic disease Any condition preventing safe implantation

Primary outcome measure(s)

Successful administration of iDose TR in an office-based surgical setting. — 3 months
Number of subjects that received iDose TR in an office-based surgical setting by the Investigator.

Trial sites (1)

Facility	City	Region	Status
Glaukos Investigative Site	Austin	Texas	Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07816692 on ClinicalTrials.gov ↗ ← All trials in the USA